KRAS and cancer: Unbiased analyses identified cancer-elaborated CXCL1/PPBP, potent myeloid cell chemoattractants that drive inflammation and metastasis via CXCR1/CXCR2 on host cells57,58, as the transcriptional targets of IL-1β-fostered KRAS-IKKα addiction.